🇺🇸 FDA
Patent

US 12325753

Method of using an anti-transferrin receptor antibody to deliver an oligonucleotide to a subject having facioscapulohumeral muscular dystrophy

granted A61KA61K2039/505A61K47/6807

Quick answer

US patent 12325753 (Method of using an anti-transferrin receptor antibody to deliver an oligonucleotide to a subject having facioscapulohumeral muscular dystrophy) held by Dyne Therapeutics, Inc. expires Mon Jun 05 2045 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Dyne Therapeutics, Inc.
Grant date
Tue Jun 10 2025 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jun 05 2045 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
30
CPC classes
A61K, A61K2039/505, A61K47/6807, A61K47/6849, A61K47/6889